Humana Inc. (NYSE:HUM) Receives Consensus Rating of “Hold” from Analysts

Humana Inc. (NYSE:HUM) has earned a consensus rating of “Hold” from the twenty-one analysts that are presently covering the firm, Marketbeat reports. Twelve analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $423.63.

Several equities analysts have recently weighed in on the stock. Raymond James initiated coverage on shares of Humana in a research note on Friday, March 22nd. They issued a “market perform” rating for the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $360.00 price target on shares of Humana in a research note on Wednesday, June 12th. Bank of America boosted their price objective on shares of Humana from $342.00 to $376.00 and gave the stock a “neutral” rating in a report on Monday, May 20th. Oppenheimer lowered their price target on shares of Humana from $415.00 to $370.00 and set an “outperform” rating for the company in a report on Thursday, April 25th. Finally, Barclays lowered their price target on shares of Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a report on Tuesday, April 2nd.

Hedge Funds Weigh In On Humana

Several hedge funds and other institutional investors have recently bought and sold shares of HUM. Paralel Advisors LLC lifted its stake in shares of Humana by 1.3% in the 3rd quarter. Paralel Advisors LLC now owns 3,944 shares of the insurance provider’s stock worth $1,919,000 after purchasing an additional 49 shares during the period. Kestra Advisory Services LLC raised its stake in Humana by 12.4% during the 3rd quarter. Kestra Advisory Services LLC now owns 3,542 shares of the insurance provider’s stock worth $1,723,000 after acquiring an additional 391 shares during the period. QRG Capital Management Inc. bought a new stake in Humana during the 3rd quarter worth approximately $2,496,000. Envestnet Asset Management Inc. raised its stake in Humana by 29.9% during the 3rd quarter. Envestnet Asset Management Inc. now owns 235,584 shares of the insurance provider’s stock worth $114,617,000 after acquiring an additional 54,205 shares during the period. Finally, Envestnet Portfolio Solutions Inc. bought a new stake in Humana during the 3rd quarter worth approximately $1,221,000. Institutional investors own 92.38% of the company’s stock.

Humana Trading Down 1.6 %

NYSE:HUM opened at $349.55 on Wednesday. The stock has a market capitalization of $42.12 billion, a price-to-earnings ratio of 21.77, a PEG ratio of 2.10 and a beta of 0.52. The firm has a fifty day simple moving average of $337.79 and a two-hundred day simple moving average of $357.54. Humana has a 12 month low of $298.61 and a 12 month high of $530.54. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.77.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The company had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same period last year, the firm earned $9.38 earnings per share. The firm’s revenue was up 10.7% on a year-over-year basis. Analysts expect that Humana will post 16.07 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.01%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s dividend payout ratio is currently 22.04%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.